Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas—the most common type of adult brain cancer—and nucleotide sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.

Joshua M. Korn | Christopher A. Miller | Derek Y. Chiang | Benjamin E. Gross | Nicholas J. Wang | Amy E. Hawkins | Brian H. Dunford-Shore | D. Absher | T. Fennell | K. Cibulskis | S. Gabriel | J. Mesirov | E. Lander | C. Sander | G. Sherlock | R. Wilson | R. Fulton | G. Weinstock | E. Mardis | R. Gibbs | P. Spellman | M. Bittner | R. Myers | T. Golub | L. Chin | G. Getz | M. Meyerson | Huy Nguyen | L. Fulton | J. Baldwin | Michael Reich | M. Berger | F. Collins | J. Brooks | A. Southwick | W. Gerald | C. Perou | T. Speed | J. Weinstein | P. Park | A. Lapuk | H. Feiler | J. Gray | M. Robinson | R. McLendon | A. Friedman | D. Bigner | Erwin G. Van Meir | D. Brat | Gena M Mastrogianakis | J. Olson | T. Mikkelsen | N. Lehman | K. Aldape | W. Yung | O. Bogler | S. Vandenberg | M. Prados | D. Muzny | M. Morgan | S. Scherer | A. Sabo | L. Nazareth | L. Lewis | O. Hall | Yiming Zhu | Yanru Ren | Omar Alvi | Jiqiang Yao | A. Hawes | S. Jhangiani | G. Fowler | A. Lucas | C. Kovar | A. Cree | H. Dinh | J. Santibanez | V. Joshi | M. Gonzalez-Garay | A. Milosavljevic | L. Donehower | D. Wheeler | C. Sougnez | Scott Mahan | Jane Wilkinson | L. Ziaugra | R. Onofrio | T. Bloom | R. Nicol | K. Ardlie | L. Ding | M. McLellan | J. Wallis | D. Larson | Xiaoqi Shi | R. Abbott | Ken Chen | D. Koboldt | M. Wendl | R. Meyer | Yuzhu Tang | Ling Lin | John R. Osborne | T. Miner | K. Delehaunty | C. Markovic | Gary W. Swift | W. Courtney | C. Pohl | S. Abbott | Shin Leong | C. Haipek | Heather K. Schmidt | M. Wiechert | T. Vickery | S. Scott | D. Dooling | A. Chinwalla | W. Winckler | R. Verhaak | M. Lawrence | Michael J. T. O’Kelly | James Robinson | G. Alexe | R. Beroukhim | S. Carter | Josh Gould | Supriya Gupta | J. Korn | C. Mermel | S. Monti | Melissa Parkin | Nicolas Stransky | B. Weir | L. Garraway | A. Protopopov | Jianhua Zhang | I. Perna | Sandy Aronson | N. Sathiamoorthy | Georgi Ren | Jun Yao | W. Wiedemeyer | Hyun Soo Kim | Won Kong Sek | Yonghong Xiao | I. Kohane | J. Seidman | R. Kucherlapati | P. Laird | L. Cope | J. Herman | D. Weisenberger | F. Pan | D. V. Berg | L. V. Neste | Mingyu Joo | K. Schuebel | S. Baylin | Jun Z. Li | S. Brady | A. Aggarwal | Tisha Chung | E. Purdom | L. Jakkula | H. Marr | S. Dorton | Gi Choi Yoon | Ju Han | A. Ray | V. Wang | S. Durinck | K. Vranizan | V. Peng | E. V. Name | G. Fontenay | J. Ngai | J. Conboy | B. Parvin | C. Brennan | N. Socci | A. Olshen | B. Taylor | A. Lash | N. Schultz | B. Reva | Yevgeniy Antipin | A. Stukalov | E. Cerami | Qingqing Wei | L. Qin | V. Seshan | Liliana Villafania | Magali Cavatore | L. Borsu | A. Viale | M. Ladanyi | D. Hayes | M. D. Topal | K. Hoadley | Yuan Qi | S. Balu | Yan Shi | Junyuan Wu | R. Penny | T. Shelton | E. Lenkiewicz | S. Morris | D. Beasley | Sheri Sanders | A. Kahn | R. Sfeir | Jessica Chen | D. Nassau | L. Feng | E. Hickey | A. Barker | D. Gerhard | J. Vockley | C. Compton | J. Vaught | P. Fielding | M. Ferguson | C. Schaefer | Jinghui Zhang | S. Madhavan | K. Buetow | P. Good | M. Guyer | B. Ozenberger | J. Peterson | E. Thomson | Audrey M. Southwick | Kornel E. Schuebel | Shannon T. Brady | Subha Madhavan | Vandita Joshi | S. Aronson | Larry Feng | Alexey Stukalov | Huy L. Nguyen | M. Reich | N. Stransky | Toby Bloom | R. Wilson | D. Muzny | Jane L. Peterson | Andrew Cree | J. Gray | Gabriele Alexe | Liliana B Villafania

[1]  P. Humphrey,et al.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. James,et al.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Neumann,et al.  Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. , 1995, Anticancer research.

[4]  M. Dolan,et al.  Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.

[5]  D. Cooper,et al.  Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene , 1996, Human Genetics.

[6]  C. Moorehead All rights reserved , 1997 .

[7]  M. Cayouette,et al.  Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. , 1997, The New England journal of medicine.

[8]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[9]  P. Nürnberg,et al.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. , 2000, American journal of human genetics.

[10]  Karlyne M. Reilly,et al.  Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.

[11]  G Mortier,et al.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.

[12]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[13]  M. Berger,et al.  Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. , 2003, Journal of neurosurgery.

[14]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[15]  Paul S Mischel,et al.  Targeted Molecular Therapy of GBM , 2003, Brain pathology.

[16]  Paul S Mischel,et al.  Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.

[17]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[18]  Finn Drabløs,et al.  Alkylation damage in DNA and RNA--repair mechanisms and medical significance. , 2004, DNA repair.

[19]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[20]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[21]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[22]  Catherine L Nutt,et al.  Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas , 2004, Brain pathology.

[23]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[24]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Dawen Zhao,et al.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. , 2005, Cancer cell.

[26]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[27]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[28]  Gary L Gallia,et al.  PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.

[29]  L. Chin,et al.  Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. , 2006, Cancer research.

[30]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Roberts,et al.  Human tumor mutants in the p110alpha subunit of PI3K. , 2006, Cell cycle.

[32]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[33]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.

[34]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[35]  S. Gabriel,et al.  Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.

[36]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[37]  Bert Vogelstein,et al.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.

[38]  Rebecca A Betensky,et al.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[40]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[41]  K. Kinzler,et al.  The Structure of a Human p110a/p85a Complex Elucidates the Effects of Oncogenic PI3Ka Mutations , 2007 .

[42]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[43]  Guy Cavet,et al.  Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.

[44]  L. Mario Amzel,et al.  The Structure of a Human p 110 a / p 85 a Complex Elucidates the Effects of Oncogenic PI 3 K a Mutations , 2007 .

[45]  Guojun Wu,et al.  Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells , 2008, Breast Cancer Research and Treatment.

[46]  P. A. Futreal,et al.  Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.

[47]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[48]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[49]  M. Bignami,et al.  Role of mismatch repair and MGMT in response to anticancer therapies. , 2008, Anti-cancer agents in medicinal chemistry.

[50]  R. Mason,et al.  Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.

[51]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[52]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Webster K. Cavenee,et al.  Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.

[54]  E. Kohn,et al.  Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency , 2008, International journal of cancer.

[55]  C. Sander,et al.  Functional Copy-Number Alterations in Cancer , 2008, PloS one.